Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2006 1
2007 1
2008 1
2010 1
2011 1
2012 1
2013 3
2014 1
2015 1
2016 1
2017 1
2018 2
2019 5
2020 6
2021 2
2022 3
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells.
Seung E, Xing Z, Wu L, Rao E, Cortez-Retamozo V, Ospina B, Chen L, Beil C, Song Z, Zhang B, Levit M, Deng G, Hebert A, Kirby P, Li A, Poulton EJ, Vicente R, Garrigou A, Piepenhagen P, Ulinski G, Sanicola-Nadel M, Bangari DS, Qiu H, Pao L, Wiederschain D, Wei R, Yang ZY, Nabel GJ. Seung E, et al. Among authors: qiu h. Nature. 2022 Mar;603(7900):328-334. doi: 10.1038/s41586-022-04439-0. Epub 2022 Feb 23. Nature. 2022. PMID: 35197632
Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation.
Wu L, Seung E, Xu L, Rao E, Lord DM, Wei RR, Cortez-Retamozo V, Ospina B, Posternak V, Ulinski G, Piepenhagen P, Francesconi E, El-Murr N, Beil C, Kirby P, Li A, Fretland J, Vicente R, Deng G, Dabdoubi T, Cameron B, Bertrand T, Ferrari P, Pouzieux S, Lemoine C, Prades C, Park A, Qiu H, Song Z, Zhang B, Sun F, Chiron M, Rao S, Radošević K, Yang ZY, Nabel GJ. Wu L, et al. Among authors: qiu h. Nat Cancer. 2020 Jan;1(1):86-98. doi: 10.1038/s43018-019-0004-z. Epub 2019 Nov 18. Nat Cancer. 2020. PMID: 35121834
XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer.
Jenkins KA, Park M, Pederzoli-Ribeil M, Eskiocak U, Johnson P, Guzman W, McLaughlin M, Moore-Lai D, O'Toole C, Liu Z, Nicholson B, Flesch V, Qiu H, Clackson T, O'Hagan RC, Rodeck U, Karow M, O'Neil J, Williams JC. Jenkins KA, et al. Among authors: qiu h. J Immunother Cancer. 2023 Dec 12;11(12):e007785. doi: 10.1136/jitc-2023-007785. J Immunother Cancer. 2023. PMID: 38164757 Free PMC article.
Site-Specific Antibody Conjugation to Engineered Double Cysteine Residues.
Zhou Q, Kyazike J, Boudanova E, Drzyzga M, Honey D, Cost R, Hou L, Duffieux F, Brun MP, Park A, Qiu H. Zhou Q, et al. Among authors: qiu h. Pharmaceuticals (Basel). 2021 Jul 14;14(7):672. doi: 10.3390/ph14070672. Pharmaceuticals (Basel). 2021. PMID: 34358098 Free PMC article.
Engineered Fc-glycosylation switch to eliminate antibody effector function.
Zhou Q, Jaworski J, Zhou Y, Valente D, Cotton J, Honey D, Boudanova E, Beninga J, Rao E, Wei R, Mauriac C, Pan C, Park A, Qiu H. Zhou Q, et al. Among authors: qiu h. MAbs. 2020 Jan-Dec;12(1):1814583. doi: 10.1080/19420862.2020.1814583. MAbs. 2020. PMID: 32892677 Free PMC article.
Engineering an anti-CD52 antibody for enhanced deamidation stability.
Qiu H, Wei R, Jaworski J, Boudanova E, Hughes H, VanPatten S, Lund A, Day J, Zhou Y, McSherry T, Pan CQ, Sendak R. Qiu H, et al. MAbs. 2019 Oct;11(7):1266-1275. doi: 10.1080/19420862.2019.1631117. Epub 2019 Jul 18. MAbs. 2019. PMID: 31199181 Free PMC article.
34 results